Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis
- PMID: 29347812
- PMCID: PMC6823568
- DOI: 10.3904/kjim.2017.098
Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis
Abstract
Background/aims: Methicillin-resistant Staphylococcus aureus (MRSA) is highly prevalent in hospitals, and has recently emerged in the community. The impact of methicillin-resistance on mortality and medical costs for patients with S. aureus bacteremia (SAB) requires reevaluation.
Methods: We searched studies with SAB or endocarditis using electronic databases including Ovid-Medline, Embase-Medline, and Cochrane Library, as well as five local databases for published studies during the period January 2000 to September 2011.
Results: A total of 2,841 studies were identified, 62 of which involved 17,563 adult subjects and were selected as eligible. A significant increase in overall mortality associated with MRSA, compared to that with methicillin-susceptible S. aureus (MSSA), was evidenced by an odds ratio (OR) of 1.95 (95% confidence interval [CI], 1.73 to 2.21; p < 0.01). In 13 endocarditis studies, MRSA increased the risk of mortality, with an OR of 2.65 (95% CI, 1.46 to 4.80). When three studies, which compared mortality rates between CA-MRSA and CA-MSSA, were combined, the risk of methicillin-resistance increased 3.23-fold compared to MSSA (95% CI, 1.25 to 8.34). The length of hospital stay in the MRSA group was 10 days longer than that in the MSSA group (95% CI, 3.36 to 16.70). Of six studies that reported medical costs, two were included in the analysis, which estimated medical costs to be $9,954.58 (95% CI, 8,951.99 to 10,957.17).
Conclusion: MRSA is still associated with increased mortality, longer hospital stays and medical costs, compared with MSSA in SAB in studies published since the year 2000.
Keywords: Bacteremia; Endocarditis; Methicillin resistance; Mortality; Staphylococcus aureus.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures




Similar articles
-
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia.Infect Control Hosp Epidemiol. 2005 Feb;26(2):175-83. doi: 10.1086/502523. Infect Control Hosp Epidemiol. 2005. PMID: 15756889
-
Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study.BMC Infect Dis. 2011 Oct 31;11:298. doi: 10.1186/1471-2334-11-298. BMC Infect Dis. 2011. PMID: 22040268 Free PMC article.
-
Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.Clin Infect Dis. 2008 Mar 15;46(6):799-806. doi: 10.1086/527389. Clin Infect Dis. 2008. PMID: 18266610
-
Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.Crit Care. 2017 Aug 14;21(1):211. doi: 10.1186/s13054-017-1801-3. Crit Care. 2017. PMID: 28807042 Free PMC article. Review.
-
[Infective endocarditis as cardiovascular emergency].Internist (Berl). 2010 Aug;51(8):987-94. doi: 10.1007/s00108-009-2538-0. Internist (Berl). 2010. PMID: 20503033 Review. German.
Cited by
-
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.Antimicrob Agents Chemother. 2019 Jun 24;63(7):e02252-18. doi: 10.1128/AAC.02252-18. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 30988146 Free PMC article. Clinical Trial.
-
Thirty-Day Mortality of Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Insights from a Retrospective Cohort Study.Yonsei Med J. 2024 Dec;65(12):770-776. doi: 10.3349/ymj.2023.0600. Yonsei Med J. 2024. PMID: 39609092 Free PMC article.
-
The Evolving Landscape of Infective Endocarditis: Difficult-to-Treat Resistance Bacteria and Novel Diagnostics at the Foreground.J Clin Med. 2025 Mar 19;14(6):2087. doi: 10.3390/jcm14062087. J Clin Med. 2025. PMID: 40142895 Free PMC article. Review.
-
Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.BMC Infect Dis. 2020 Feb 21;20(1):160. doi: 10.1186/s12879-020-4895-1. BMC Infect Dis. 2020. PMID: 32085732 Free PMC article.
-
Microbiological and genotypic factors affecting mortality in methicillin-resistant Staphylococcus aureus bacteremia.Korean J Intern Med. 2019 Jan;34(1):63-64. doi: 10.3904/kjim.2018.435. Epub 2018 Dec 28. Korean J Intern Med. 2019. PMID: 30612420 Free PMC article. No abstract available.
References
-
- Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–59. - PubMed
-
- Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999;20:408–411. - PubMed
-
- Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003;290:2976–2984. - PubMed
-
- Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis. 2006;42:647–656. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical